Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics.

Front Immunol · 2022 · PMC9846605 · PMID 36685577

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

marginally significantp = 0.057so close (0.05 < p ≤ 0.1)

However, comparing the efficacy of the combination relative to the efficacy of its separate components, we found that anti CTLA-4 + cisplatin had a marginally significant ( p = 0.057) synergistic effect relative to either anti CTLA-4 or cisplatin alone.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.